Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03845517 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study TO Evaluate Efficacy AND Safety OF PF-06700841 IN Systemic Lupus Erythematosus (SLE)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
NCT03845517: Completed Phase 2 study, sponsored by Pfizer.
NCT03845517 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 350 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (163% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03845517, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
Study Summary
Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.
Primary Outcome
SRI-4 components included Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), British Isles Lupus Assessment Group (BILAG) 2004 and Physician's Global Assessment (PhGA). Participants were classified as SRI-4 responders, if they met all of the following criteria compared with baseline: 1) greater than or equal to (\>=) 4 point reduction in SLEDAI-2K score; 2) no new BILAG A organ domain score or 2 new BILAG B organ domain scores; 3) no worsening (less than \[\<\] 0.3 point incre
Interventions
- DRUG Placebo
- DRUG PF-06700841 15 mg
- DRUG PF-06700841 30 mg
- DRUG PF-06700841 45 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2019-04-18 |
| Est. Completion | 2023-10-05 |
| Phase | Phase 2 |
What the finished NCT03845517 record still lists
NCT03845517 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (163% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03845517 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03845517 about?
NCT03845517 is a clinical study titled "A Dose-ranging Study TO Evaluate Efficacy AND Safety OF PF-06700841 IN Systemic Lupus Erythematosus (SLE)". Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.
What is the current status of trial NCT03845517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2019-04-18. Estimated completion is 2023-10-05.
What interventions are being tested in trial NCT03845517?
The interventions under investigation include: Placebo (DRUG), PF-06700841 15 mg (DRUG), PF-06700841 30 mg (DRUG), PF-06700841 45 mg (DRUG).
Who is sponsoring clinical trial NCT03845517?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03845517's enrollment target sits among peer trials
350 130th of 2000 higher than 1,865 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI